权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

The Ohio State University and MD Anderson Cancer Center Thyroid Cancer SPORE

俄亥俄州立大学和 MD 安德森癌症中心甲状腺癌孢子

基本信息

批准号：
8741949
负责人：
Matthew D Ringel
金额：
$ 216.2万
依托单位：
OHIO STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-09-25 至 2018-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8741949
关键词：
Accounting Address Adverse effects Area Behavior Biological Biological Assay Biological Markers Biological Process Cancer Center Cancer Detection Cancer Patient Cancer Survivor Candidate Disease Gene Case-Control Studies Cells Cessation of life Clinical Management Clinical Research Clinical Trials Combined Modality Therapy Complication Continuance of life Cyclin-Dependent Kinases DNA Dental Detection Development Diagnosis Disease Disease Outcome Distant Metastasis Doctor of Medicine Drug resistance Early Diagnosis Functional disorder Genes Genetic Goals Incidence Individual Indolent Institution Intervention Knowledge Life Long Term Survivorship MEKs Malignant Neoplasms Malignant neoplasm of thyroid Measures Molecular Abnormality Monitor Mutation Neoplasm Circulating Cells Neoplasm Metastasis Ohio Outcome Pain Papillary thyroid carcinoma Partial Remission Pathway interactions Patients Penetrance Phase II Clinical Trials Play Population Predisposition Preventive Property Prospective Studies Proteomics Publishing Quality of life Radioactive Iodine Recording of previous events Recurrence Reporting Research Research Personnel Resistance Risk Role Salivary Glands Stable Disease Taste Perception Testing Therapeutic Transcript Translational Research Translational Research Working Group Translations United States Universities University of Texas M D Anderson Cancer Center Untranslated RNA Validation Woman Xerostomia base cancer risk cancer stem cell career clinical care clinical practice experience genome wide association study improved in vivo inhibitor/antagonist medullary thyroid carcinoma meetings men mortality novel novel strategies patient population prevent programs response survivorship tumor tumor progression

项目摘要

DESCRIPTION (provided by applicant): The primary goal of The Ohio State University / M.D. Anderson Thyroid Cancer SPORE is to improve the outcomes and lives of patients with thyroid cancer by identifying genetically "at-risk" individuals allowing for early diagnosis and prediction of tumor behavior, developing new approaches to minimize side effects of treatments, and developing better biomarkers and treatment options for progressive metastatic disease. Several factors support the importance of applying these efforts to thyroid cancer: 1) Thyroid cancer incidence is rising at the fastest rate of all malignancies in the United States and worldwide; it s now the 5th most common malignancy in women and 11th most common in men. 2) Thyroid cancer typically takes an indolent course, thus with the increasing incidence there is an ever enlarging population of individuals (-500,000) surviving long term, many of whom suffer from lifelong effects of initial therapy. 3) For patients with more aggressive forms of thyroid cancer, such as medullary cancer (MTC), there exist no curative therapies or biomarkers that accurately predict outcome from disease or response to particular treatments thereby limiting efforts to individualize therapeutic intensity. In order to achieve our goals, this SPORE application proposes to support a multi-institutional team of experienced investigators from two of the leading institutions in the field with a history of collaborative clinical trials. We have chosen t focus on critical areas of need for rapid translation into clinical practice for thyroid cancer patients with the following four Projects supported by outstanding Cores: 1) Low-penetrance genes in the predisposition to papillary thyroid carcinoma; 2) Biomarker discovery and personalized intervention of radioiodine induced salivary gland damage in thyroid cancer patients; 3) Developing combination therapies for Medullary Thyroid Cancer; and 4) Development and validation of novel circulating medullary thyroid cancer markers. Through these translational Projects, as well as Career Developmental and Developmental Research Programs, we aim to impact on critical areas of need in thyroid cancer clinical management for all forms of thyroid cancer.

描述(申请人提供)：俄亥俄州立大学/安德森医学博士甲状腺癌孢子的主要目标是通过识别基因高危个体来早期诊断和预测，从而改善甲状腺癌患者的预后和生活。研究肿瘤行为，开发将治疗副作用降至最低的新方法，以及为进行性转移性疾病开发更好的生物标志物和治疗选择。有几个因素支持将这些努力应用于甲状腺癌的重要性：1)甲状腺癌发病率在美国和世界范围内以所有恶性肿瘤中最快的速度上升；S现在女性最常见的恶性肿瘤中排名第五，男性最常见的恶性肿瘤中排名第11。2)甲状腺癌通常具有缓慢的病程，因此随着发病率的增加，长期生存的个体人口不断扩大(-50万)，其中许多人遭受初始治疗的终生影响。3)对于更具侵袭性的甲状腺癌患者，如髓样癌(MTC)，目前还没有根治疗法或生物标志物来准确预测疾病的结果或对特定治疗的反应，从而限制了个性化治疗强度的努力。为了实现我们的目标，这一孢子应用程序建议支持一个由来自该领域两家具有合作临床试验历史的领先机构的经验丰富的研究人员组成的多机构团队。我们选择将重点放在甲状腺癌患者需要快速转化为临床实践的关键领域，以下四个项目得到了杰出核心的支持：1)低外显性基因与甲状腺乳头状癌的易感性；2)甲状腺癌患者放射性碘引起唾液腺损害的生物标记物的发现和个性化干预；3)开发甲状腺髓样癌的综合疗法；以及4)新的循环甲状腺髓样癌标记物的开发和验证。通过这些翻译项目，以及职业发展和发展研究计划，我们的目标是在所有形式的甲状腺癌的甲状腺癌临床管理的关键领域产生影响。